PTEN Inhibition in Human Disease Therapy
AbstractThe tumor suppressor PTEN is a major homeostatic regulator, by virtue of its lipid phosphatase activity against phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3], which downregulates the PI3K/AKT/mTOR prosurvival signaling, as well as by its protein phosphatase activity towards specific protein targets. PTEN catalytic activity is crucial to control cell growth under physiologic and pathologic situations, and it impacts not only in preventing tumor cell survival and proliferation, but also in restraining several cellular regeneration processes, such as those associated with nerve injury recovery, cardiac ischemia, or wound healing. In these conditions, inhibition of PTEN catalysis is being explored as a potentially beneficial therapeutic intervention. Here, an overview of human diseases and conditions in which PTEN inhibition could be beneficial is presented, together with an update on the current status of specific small molecule inhibitors of PTEN enzymatic activity, their use in experimental models, and their limitations as research or therapeutic drugs. View Full-Text
Share & Cite This Article
Pulido, R. PTEN Inhibition in Human Disease Therapy. Molecules 2018, 23, 285.
Pulido R. PTEN Inhibition in Human Disease Therapy. Molecules. 2018; 23(2):285.Chicago/Turabian Style
Pulido, Rafael. 2018. "PTEN Inhibition in Human Disease Therapy." Molecules 23, no. 2: 285.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.